Vicore Pharma Shares and Votes Increased

May 31, 2024, Vicore Pharma has reported an increase in the number of its shares and votes. This development follows the exercise of warrants, leading to the issuance of shares to a participant in the incentive program Board LTIP 2023. Specifically, 11,025 share rights were exercised, resulting in the issuance of an equivalent number of shares.

As a result of these share awards, the number of outstanding shares and votes in Vicore Pharma has risen by 11,025, leading to an increase in share capital by 5,512.499947 SEK. As of the current date, the total registered shares and votes in the company amount to 111,734,004. Correspondingly, the registered share capital now stands at 55,867,001.457610 SEK.

About Vicore Pharma Holding AB

Vicore Pharma is a clinical-stage biopharmaceutical company that is pioneering a new class of drugs with the potential to modify diseases. The company is focused on developing treatments for respiratory diseases, with a particular emphasis on idiopathic pulmonary fibrosis (IPF). One of their leading compounds, Buloxibutid (C21), is an orally available small molecule that acts as an angiotensin II type 2 receptor agonist (ATRAG). This drug has recently completed a phase 2a study in IPF, showcasing its potential.

In addition to pharmaceuticals, Vicore is also advancing Almee™, an investigational medical device currently in clinical development. Almee™ is a digital therapeutic based on cognitive behavioral therapy, designed to address the psychological challenges associated with pulmonary fibrosis. The device has received Breakthrough Device Designation from the FDA, indicating its potential to provide significant improvements in the standard of care.

Vicore Pharma's expertise in ATRAG chemistry and biology is driving the expansion of their drug pipeline, with several new therapies under development for various indications. The company's commitment to innovation and therapeutic advancement is reflected in their rigorous clinical trials and continuous research efforts.

Vicore Pharma Holding AB's shares are traded on Nasdaq Stockholm's main market under the ticker symbol VICO. The company is dedicated to maintaining transparency and compliance with the Financial Instruments Trading Act, which mandates the public disclosure of pertinent information.

Summary

Vicore Pharma Holding AB has announced an increase in its share and vote count following the exercise of warrants by a participant in their incentive program, resulting in the issuance of 11,025 new shares. This event has raised the company's total outstanding shares and votes to 111,734,004 and increased the share capital to 55,867,001.457610 SEK. Vicore Pharma, a clinical-stage biopharmaceutical company, continues to advance its portfolio in respiratory diseases, notably with its lead compound Buloxibutid (C21) and the digital therapeutic Almee™. The company remains a key player in developing innovative treatments for diseases like idiopathic pulmonary fibrosis.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!